Fingerprint
Dive into the research topics of 'Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically